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Background: The consensus statement on the Diagnosis and Therapy of Idiopathic Pulmonary
Fibrosis (IPF) formulated by the American Thoracic Society/European Respiratory Society
(ATS/ERS) was published in 2000. Acceptance and implementation of these guidelines have
not been assessed. We surveyed the fellows of the American College of Chest Physicians (FCCP)
to establish current practice patterns regarding the diagnosis and therapy of IPF.
Methods: We electronically distributed a 32-item questionnaire to all 6443 pulmonary medicine
board-certified Fellows of the American College of Chest Physicians. The response rate was 13%.
Demographic characteristics were similar between respondents and non-respondents.
Results: Seventy-two percent of respondents were familiar with the ATS/ERS consensus state-
ment and 63% found it clinically useful. However, a similar number of respondents indicated that
an update is needed. Bronchoscopy and surgical lung biopsy are used infrequently. Forty-five per-
cent of pulmonary physicians advocate providing only supportive care for patients outside of clin-
ical trials. If pharmacological therapy is recommended, prednisone (either alone or in
combination with azathioprine) or off-label agents are preferentially prescribed. Despite physi-
cian awareness (79%) of clinical trials, interested patients are not consistently referred (54%). A
majority of respondents (61%) felt that lung transplantation represents the only effective ther-
apy for IPF, and 86% refer their patients to lung transplant centers.e of Chest Physicians; ANA, antinuclear antibodies; ATS, American Thoracic Society; ENA, extractable
ratory Society; FCCP, Fellow of the American College of Chest Physicians; HRCT, high-resolution com-
ng diseases; IPF, idiopathic pulmonary fibrosis; RF, rheumatoid factor; TTE, transthoracic echocardi-
onia.
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Assessment of current practice in the diagnosis and therapy 1343Conclusions: There is substantial variability among pulmonary physicians in the diagnosis and
management of IPF. This may, in part, reflect the current lack of effective pharmacologic ther-
apy. Updated practice guidelines are needed for the diagnosis and therapy of IPF.
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Idiopathic pulmonary fibrosis (IPF) is a devastating,
progressive lung disease as illustrated by a median survival
from diagnosis of approximately 3 years.1 Over the past
decade there have been several conceptual changes in
the diagnostic and therapeutic approach to patients with
IPF.2e4 In the year 2000, the American Thoracic Society
(ATS) and European Respiratory Society (ERS) published
a joint international consensus statement incorporating
these new developments.1 This document defined IPF as
a progressive chronic interstitial lung disease of unknown
cause associated with a histopathologic pattern of usual in-
terstitial pneumonia (UIP).1 Patients with compatible clini-
cal and radiologic features combined with a histopathologic
confirmation of UIP on surgical lung biopsy have ‘‘definite’’
IPF.1 A diagnosis of ‘‘probable’’ IPF is assigned if several
clinical and radiologic criteria are met in the absence of
a surgical lung biopsy.1 Several high-resolution computer
tomographic (HRCT) findings have been delineated that
correlate with the histopathologic pattern of UIP.5e8
While new diagnostic criteria have been developed,
treatment of IPF remains difficult.1 In the absence of effec-
tive therapy, the ATS/ERS document suggests combination
therapy with prednisone and azathioprine or cyclophospha-
mide as an option for initial treatment.1 In recent years,
several studies have suggested possible therapeutic effects
from non-immunosuppressive agents such as N-acetylcys-
teine and anticoagulation in patients with IPF.9,10 In
addition, several new pharmacologic agents (e.g. inter-
feron-gamma, pirfenidone, etanercept, imatinib, and
bosentan) have been investigated in clinical trials.11,12
The goal of this survey was to assess current practice
patterns and attitudes of pulmonologists in the diagnosis
and management of patients with IPF. Furthermore, we
hoped to identify current dilemmas and additional issues
that may need to be addressed in forthcoming practice
guidelines.
Methods
We designed a 32-item questionnaire to characterize
current clinical practice patterns regarding the evaluation
and treatment of IPF patients by pulmonologists (see online
supplement for questionnaire).
This questionnaire was developed to specifically collect
data regarding:
1. Familiarity with and utilization of the ATS/ERS consen-
sus statement on IPF1 (2 questions).
2. Current diagnostic strategies employed for patients
with suspected IPF (11 questions).
3. Therapeutic interventions recommended for patients
diagnosed as having IPF (11 questions).In addition, we gathered demographics of the respon-
dents and data regarding the frequency with which they
encountered IPF patients (8 questions).
We used the software SurveyTracker (TrainingTechnolo-
gies, Lebanon, OH) to convert the questionnaire into an online
survey. The online survey was piloted within the Division of
Pulmonary and Critical Care Medicine at the Mayo Clinic,
Rochester, MN. Based on the comments received, wemodified
the survey. The American College of Chest Physicians (ACCP)
approved this online survey as an ACCP-Interstitial Lung
Diseases (ILD) Network project. The Mayo Clinic Institutional
Review Board also approved this project.
On December 15, 2006, an e-mail announcing the
upcoming IPF survey was sent to all Fellows of the American
College of Chest Physicians (FCCP) who are board-certified
in Pulmonary Medicine (nZ 6443). This announcement was
followed on December 18, 2006 by another e-mail providing
the recipients with a link to the online survey. A reminder
was sent to all potential participants on January 3, 2007
and the survey closed on January 17, 2007. All responses
were electronically collected, summarized and analyzed
using the SurveyTracker (TrainingTechnologies, Lebanon,
OH) software. All data were de-identified.
The Chi-Square test (c2) (GraphPad Software, San Diego,
CA) was used to compare the demographics of the respon-
dents and all potential participants, and to perform the
subgroup analysis by the year of fellowship completion
and practice setting. Respondents practicing in both private
and academic settings responded similarly to pulmonary
physicians in private practice and were therefore combined
for subgroup analysis.Results
Eight hundred and fourteen individuals (13%) of the invited
physicians completed the survey; 36 individuals stated that
they do not encounter patients with interstitial lung
diseases (ILD) and were excluded. The median response
rate of all respondents to the individual questions was
99.6% (range, 77.1e100%).
Table 1 compares the demographics for the 778 respon-
dents and the entire cohort of the invited participants.
There were no significant differences between the invited
participants and the respondents in regard to gender,
year of fellowship completion, and practice location.
Compared to the invited cohort, the survey respondents
tended to be slightly younger (pZ 0.32).
Since the ACCPmembership database does not include any
information about the practice setting we were unable to
compare the respondents to the entire cohort in this regard.
The survey respondents have a substantial ILD/IPF
practice. Sixty-six percent of respondents saw at least 2
ILD patients per week and 38% of the respondents evalu-
ated at least 2 IPF patients per week (Fig. 1).
Table 1 Comparison of demographic information be-












41e50 years 38 38
51e60 years 35 38
Over 60 years 18 10
Gender (%)
Men 88 87 0.83
Women 12 13
Year of completion of fellowship (%)
Before 1990 50 51 0.92
1990e2000 35 36
After 2000 15 13
Practice location (%)
US 85 82 0.70
Outside US 15 18
Practice setting (%)
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IPF consensus statement
Seventy-two percent [95% CI 69e75%] of all respondents were
familiarwith theATS/ERSconsensus statementand63% [95%CI
59e67%] of them considered it clinically useful. The majority
of participants (63% [95%CI 58e66%]) felt that anupdateof this
consensus statement is needed. These responses did not vary
based on practice setting or time since completion of fellow-
ship training. Sixty-four percent [95% CI 60e68%] of all
participants stated that they use the diagnostic criteria for
‘‘definite’’ and ‘‘probable’’ IPF as outlined in the consensusFigure 1 Frequency of interstitial lung disease (ILD) and idi-
opathic pulmonary fibrosis (IPF) patients encountered by the
survey respondents.statement. Physicians who graduated from fellowship training
after the year 2000 or practice pulmonary medicine in an
academic setting used these criteria more commonly, gradu-
ates >2000 (75% [95% CI 65e83%]) versus 2000 (62% [95% CI
58e66%]), pZ 0.02 and physicians in academic practice (76%
[95% CI 70e82%]) versus private/academic practice (58% [95%
CI 53e63%]), p> 0.001.
Diagnosis of IPF
Seventy-three percent [95% CI 69e76%] of the respondents
obtain HRCT for every patient with suspected IPF;
academic pulmonologists reported the higher universal
utilization of HRCT (academic practice 80% [95% CI 74e
85%] versus 73% [95% CI 66e74%] private/academic prac-
tice, pZ 0.003). Most pulmonologists indicated that they
order antinuclear antibodies (ANA) (98%, 95% CI 96e99%)
and rheumatoid factor (RF) (94%, 95% CI 92e95%) [Fig. 2].
Subgroup analysis revealed significant differences regarding
the use of other serologic markers. Academic pulmonolo-
gists more commonly order anti-double-stranded DNA anti-
bodies (43% [95% CI 37e50%] versus 31% [95% CI 27e36%],
pZ 0.002), antibodies against extractable nuclear antigens
(ENA) (60% [95% CI 54e66%] versus 45% [95% CI 38e47%],
p< 0.001) and creatine kinase (42% [95% CI 35e48%] versus
27% [95% CI 22e29%], p< 0.001) compared to private/aca-
demic pulmonologists. Physicians, who graduated before
1990, less frequently order anti-ds-DNA antibodies (30%
[95% CI 26e35%] versus 42% [95% CI 35e45%], pZ 0.004)
and anti-ENA-antibodies (42% [95% CI 37e47%] versus 56%
[95% CI 48e58%], pZ 0.003) but more commonly order a hy-
persensitivity serologic panel (47% [95% CI 42e52%] versus
37% [95% CI 33e43%], pZ 0.007).
The majority of pulmonary physicians (57% [95% CI 53e
60%]) responding to our survey utilize surgical lung biopsy in
30% of patients with suspected IPF. Similarly, the majority
of respondents (62% [95% CI 58e65%]) perform bronchoscopy
in <50% of their suspected IPF cases; pulmonologists in
private/academic practice employ bronchoscopy less
frequently compared to those in academic settings (68%
[95% CI 62e70%] versus 54% [95% CI 48e60%], pZ 0.002). The
tests performed during bronchoscopy are outlined in Fig. 3.
If a surgical lung biopsy is performed, most physicians
(78% [95% CI 75e80%]) use HRCT to determine the biopsy
site; recent graduates (after the year 2000) of pulmonary
fellowship programs utilize HRCT more frequently (86%
[95% CI 78e92%] versus 77% [95% CI 73e80%], pZ 0.003) for
this purpose. Eighty percent [95% CI 77e83%] of respon-
dents request the surgeon to biopsy more than one lobe.
Recent evidence suggests that both the 6-min walk test
and transthoracic echocardiogram (TTE) can be used to risk
stratify patients with IPF. The majority of respondents
report using the 6-min walk test to assess exercise capacity
and disease progression (66% [95% CI 62e69%]), and order
TTE to evaluate patients with suspected IPF for pulmonary
hypertension (76% [95% CI 73e79%]).
Therapeutic interventions in patients with IPF
The majority of respondents (61% [95% CI 57e64%]) felt
there is currently no effective pharmacologic therapy for
Figure 2 Utilization of serologic markers in the diagnostic workup of patients with idiopathic pulmonary fibrosis. ANA, antinu-
clear antibodies; ENA, anti-extractable nuclear antigens antibodies; Anti-DS-DNA, anti-double stranded DNA antibodies; RF, rheu-
matoid factor; Anti-CCP, anti-cyclic citrullinated peptide antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; CK, creatine
kinase.
Assessment of current practice in the diagnosis and therapy 1345IPF other than lung transplantation. However, 55% [95% CI
52e59%] of the respondents stated they use pharmacolog-
ical therapy for IPF patients who are not candidates for lung
transplantation. Eighty-six percent [95% CI 83e88%] of the
respondents stated they refer their IPF patients to a lung
transplant center for evaluation.
The survey questionnaire included two case scenarios
(see online supplement) for which the respondents were
asked to select a preferred treatment regimen. The first
case illustrated a patient with histologically confirmed UIP
and radiologic features of mild IPF characterized by prom-
inence of ground-glass opacities and minimal fibrosis. In
contrast, the second case described a patient with ad-
vanced IPF including radiologic features of advanced hon-
eycombing and only minimal associated ground-glass
opacities, but without a surgical lung biopsy confirmation.
There was a broad range of responses indicating hetero-
geneity of treatment preferences. For the first case (mild
IPF), most common choices included prednisone alone (30%
[95% CI 25e34%]), combination of prednisone, azathioprine
and N-acetylcysteine (27% [95% CI 23e31%]), and predni-
sone combined with azathioprine (18% [95% CI 14e21%])
or cyclophosphamide (8% [95% CI 6e11%]). For the second
case (advanced IPF), fewer participants chose prednisone
alone (20% [95% CI 17e24%]) but the proportions favoring
the combination of prednisone, azathioprine and N-Figure 3 Bronchoscopic procedures in the diagnostic evalua-
tion of patients with idiopathic pulmonary fibrosis. BAL, bron-
choalveolar lavage; TBBx, transbronchial biopsy.acetylcysteine (27% [95% CI 23e32%]), and prednisone com-
bined with azathioprine (16% [95% CI 13e20%]) or cyclo-
phosphamide (5% [95% CI 3e8%]) were comparable to
Case 1. Overall, approximately one-half of physicians rec-
ommended therapies in accordance with the ATS/ERS IPF
consensus statement (52.5% in Case 1 and 48.5% in Case
2). Interestingly, non-immunosuppressive therapies such
as monotherapy with N-acetylcysteine (12% [95% CI 10e
16%] Case 2 versus 8% [95% CI 6e11%] Case 1), systemic anti-
coagulation (4% [95% CI 3e7%] Case 2 versus 1% [95% CI 0.4e
3%] Case 1) or off-label use of novel therapeutic agents
(11% [95% CI 9e15%] Case 2 versus 8% [95% CI 5e10%] Case
1) was more commonly suggested for the case of advanced
IPF (Case 2) (Fig. 4).
For Case 1, treatment choice varied based on the
practice setting of the respondents (academic versus
private practice, pZ 0.046). Pulmonologists in academic
practice were less likely to use prednisone alone or off-
label therapies but more commonly prescribed prednisone
in combination with azathioprine and N-acetylcysteine as
well as N-acetylcysteine alone compared to their
colleagues in private practice. No such differences were
observed for Case 2.
In general, prednisone either alone or in combination
with other immunosuppressive agents was more commonly
recommended in the first case (82% [95% CI 78e85%])
compared to the second case (69% [95% CI 64e73%]).
The majority of clinicians (79% [95% CI 76e81%]) are
aware of clinical trials in their geographic region. However,
46% [95% CI 42e50%] of respondents indicated that they do
not or only sometimes refer patients to these centers.
Pulmonologists in academic/private practice and those who
completed their fellowship training prior to 1990 reported
less consistent (‘‘always’’) referrals to clinical trials (17%
[95% CI 14e21%] private versus 21% [95% CI 21e33%]
academic, pZ 0.004 and fellowship <1990, 14% [95% CI
11e19%] versus >1990 26% [95% CI 22e32%], pZ 0.003).
Twenty-five percent [95% CI 22e28%] of respondents
reported treating all IPF patients, regardless of symptoms
for GERD. Forty-four percent [95% CI 40e48%] of the
remaining respondents reported screening all asymptom-
atic patients with IPF for gastroesophageal reflux disease
(GERD). The most commonly employed therapy was the
Figure 4 Utilization of various pharmacologic therapies for patients with idiopathic pulmonary fibrosis. (A) Case 1, patient with
histologically confirmed UIP and radiologic features of mild IPF characterized by prominence of ground-glass opacities and minimal
fibrosis. (B) Case 2, patient with advanced IPF including radiologic features of advanced honeycombing and only minimal associated
ground-glass opacities, but without a surgical lung biopsy confirmation.
Figure 5 Utilization of supportive measures in the care of
patients with idiopathic pulmonary fibrosis.
1346 T. Peikert et al.combination of lifestyle modifications and a proton pump
inhibitor (PPI).
Eighty-three percent [95% CI 80e85%] of respondents
indicated that pulmonary hypertension detected by TTE
alters their treatment approach. Most respondents (82%
[95% CI 79e84%]) considered pulmonary hypertension to be
an indicator of poor prognosis. Forty-two percent [95% CI
38e45%] of respondents contemplate vasomodulator ther-
apy and 33% [95% CI 30e37%] think about the initiation of
anticoagulant therapy for pulmonary hypertension.
The frequencies of other supportive measures are
outlined in Fig. 5. Both, referral to pulmonary rehabilita-
tion and the discussion of end of life issues were less likely
if the physicians had completed their fellowship training
prior to 1990 (76% [95% CI 71e80%] versus 87% [95% CI
83e90%], p< 0.001 and 80% [95% CI 75e83%] versus 86%
[95% CI 83e90%], pZ 0.01).
Discussion
We believe our survey to represent the largest and most
inclusive synopsis of the current approach to the diagnosis
and treatment of IPF. We were able to capture a represen-
tative sample of pulmonologists in both academic and
private practice who encounter a large number of IPF
patients indicative of a high level of clinical experience.
Our survey is the first attempt to formally assess the level
of familiarity and acceptance of the ATS/ERS consensus
statement. Seventy-two percent of our survey respondents
reported that they were familiar with the ATS/ERS consen-
sus statement. This level of familiarity compares quite
favorably to other similar guidelines. A systematic review
by Cabana et al. reported a median level of familiarity of
43.5% with a range between 11% (American College of
Physicians exercise stress testing guidelines) and 100%(Asthma guideline).13 Nevertheless, considering the contro-
versies surrounding the management of IPF patients, the
lack of familiarity with this document by 28% of the survey
participants 7 years after its publication is troublesome and
may hinder its implementation.13
The majority of the pulmonologists familiar with the
ATS/ERS statement (64%) use the diagnostic criteria pro-
vided by the consensus statement. Although these criteria
necessitate the performance of either a surgical lung biopsy
or flexible bronchoscopy with transbronchial biopsy and/or
bronchoalveolar lavage, most patients with IPF do not
appear to undergo either surgical lung biopsy or bronchos-
copy. The infrequent utilization of these procedures during
the diagnostic workup of patients with suspected IPF is
consistent with data previously reported by other authors
and may be attributable to recent advances in HRCT
diagnosis of IPF.5e8,14,15 A recent survey demonstrated
that 67.4% of the participating pulmonologists would accept
an HRCT diagnosis of IPF in the absence of a confirmatory
Assessment of current practice in the diagnosis and therapy 1347tissue biopsy.8 Our survey did not assess the reasoning
behind the respondent’s decision to not perform a surgical
lung biopsy.
In the absence of effective pharmacologic therapy, the
management of IPF patients remains contentious. Sixty-one
percent of all pulmonary specialists completing our survey
believe that besides lung transplantation there are no
effective therapeutic options. Nearly one-half of the
respondents in our survey manage their IPF patients with
supportive care alone, a trend that has been also documented
by others.14,15 For example, 77% of British pulmonary special-
ists opted to observe when presented with an elderly patient
with IPF and minimal symptoms.14 In contrast, Collard et al.
reported a conservative treatment approach by only 9% of ac-
ademic pulmonary specialists in the US.16
There was no consensus regarding choice of pharmaco-
logic agents among pulmonologists favoring pharmacother-
apy for IPF. Prednisone continues to be the most commonly
used agent, which is similar to the observations made in
other recently published studies.14,15
Overall there is a relatively low level of acceptance of
the recommendations for the diagnosis and management of
IPF provided by the ATS/ERS consensus statement. Aside
from lack of familiarity with the document, several other
factors may influence guideline adherence.13 Over the past
several years the role of HRCT and bronchoscopy in the
diagnosis of IPF has been clarified, necessitating revisions
of the original guideline published in 2000. There has also
been increasing doubt regarding the potential effectiveness
of corticosteroids and immunosuppressive agents in the
management of IPF. Accordingly, the majority of
respondents felt that the ATS/ERS guidelines need to be
updated.13
Despite the prevalent awareness of clinical trials for the
treatment of IPF, our survey showed that treating pulmo-
nologists frequently choose not to refer interested patients
for these studies. One potential reason for this phenome-
non may be the fear of adverse outcomes related to
aggressive diagnostic evaluation, e.g., surgical lung biopsy
or study drugs.17 Alternatively, these decisions could be
influenced by geographic limitations, concerns of the physi-
cians regarding placebo-controlled study design or precon-
ceived notions about the effectiveness of the study drug.
Seven years following the publication of the ATS/ERS
consensus statement, there are now several surveys assess-
ing the current strategies employed for diagnosis and
management of IPF. Collard et al. conducted an electronic
survey of academic pulmonologists in the United States.16
However, this survey had several limitations. The authors
intended to survey all pulmonologists practicing in aca-
demic centers with an accredited training program. Out
of 130 such centers, they only obtained contact information
for practitioners from 42 centers (32%).16 Because three of
the responding programs did not provide individual contact
information but distributed group e-mails, the actual num-
ber of invited individuals remains elusive. The estimated
sample included only approximately 10% of the target
group.16 Furthermore, the survey design prohibited any
comparison between responders and non-responders and
therefore prevented an assessment whether or not this
sample was representative.16 Nevertheless, compared to
our results, Collard et al. observed very similar trendsregarding the use of HRCT, bronchoscopy, surgical lung
biopsy and the evaluation of IPF patients for GERD and
the lack of consensus regarding pharmacological therapies
in their study population.16 In contrast to our survey the
physicians surveyed by Collard et al. did encounter much
fewer IPF patients than the pulmonologists participating
in our survey.16 This greater level of expertise may explain
why we documented more frequent referrals to lung trans-
plantation and higher rates of treatment strategies focusing
on observation and supportive care.16 In addition, our
survey addressed the issue of IPF-associated pulmonary
hypertension which was not addressed in the previous study
by Collard et al.
Several other recent publications also lent support to
the diagnostic and management strategies for IPF patients
observed in our survey. A recent case-based survey was
distributed to 689 consultant members of the British
Thoracic Society (370 responses [54%]). In this exercise
two of three case scenarios represented patients suffering
from IPF.14 In addition, Collard et al. recently published
a larger survey involving IPF patients and their caregivers
(>2000 members of the Coalition for Pulmonary Fibrosis,
response ratez 50% (nZ 1448)).15
There are several limitations to our study. Our survey
had a relatively low response rate, which could have been
due to several factors. In recent months multiple online
surveys have been sent to members of the pulmonary and
critical care physician community by professional subspe-
cialty organizations. Since many of these organizations
target the same individuals included in our survey, it is
possible that the participants felt overloaded with these
requests. This explanation is supported by the fact that
recent electronic surveys conducted by the ACCP have been
similarly troubled by low response rates (personal commu-
nication with ACCP). Moreover, given the current trends for
pulmonary specialists to sub-specialize within the field of
pulmonary medicine, it is possible that individuals who do
not encounter IPF patients on a regular basis elected not to
respond. Physicians responding to our survey encounter
very large numbers of ILD and IPF patients, indicating that
we were able to survey a group of pulmonogists caring for
the majority of patients with IPF. Lastly, the fact that the
initial survey invitation was sent out close to the Christmas
holidays may be another contributing factor. Nevertheless,
based on the absence of any significant difference in
demographic variables between the respondents and the
invited individuals we feel that we captured a representa-
tive population. Finally, our data only represent a snapshot
in time, are based on information reported by physicians
rather than objective data and therefore subject to recall
bias, and our survey population was restricted to members
of the ACCP who have FCCP status.
In conclusion, the results of the survey provide a synopsis
of current practice patterns in the diagnosis and manage-
ment of IPF. We identified several dilemmas regarding the
diagnosis and management of IPF. These issues include
inadequate familiarity with the practice guidelines,
absence of consensus regarding pharmacotherapy of IPF,
and a low level of referral to clinical trials.
Evolving knowledge regarding the use of HRCT and
bronchoscopy has modified the diagnostic approach to
IPF, and practice guidelines that deal with IPF diagnosis
1348 T. Peikert et al.and management need to be updated in this regard. In the
absence of effective pharmacologic therapy, the manage-
ment of patients with IPF remains difficult as reflected in
this survey. Updated guidelines will need to include
a systematic review of currently available pharmacologic
agents in the management of IPF and an encouragement for
clinicians to refer patients with IPF for clinical trials.
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